QIAGEN NV : UBS reiterates its Neutral rating -September 15, 2023 at 02:16 am EDT
Initially Neutral on the company, UBS's analyst John Sourbeer maintained his recommendation.
Stay updated with breaking news from Initially Neutral. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Initially Neutral on the company, UBS's analyst John Sourbeer maintained his recommendation.
Initially Neutral on the company, UBS's analyst Graham Doyle maintained his recommendation. The target price is still set at EUR 40.50.
Initially Neutral on the company, Berenberg's analyst Sebastian Bray maintained his recommendation. The target price is unchanged and still at EUR 20.
Initially Neutral on the company, UBS's analyst Joseph Spak maintained his recommendation. The target price has been revised upwards and is now set at USD 290, compared with USD 270 previously.
Initially Neutral on the company, Bernstein's analyst Daniel Roeska maintained his recommendation. The target price is unchanged and still at EUR 58.